Functional component of portal hypertension;Componente funcional de la hipertensión portal

Gastroenterologia y Hepatologia

Volumn 27, Issue 6, 2004, Pages 377-387

  Abraldes, J G ^a,b   Garcia Pagan J C ^c   Bosch, J ^c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ARACHIDONATE 5 LIPOXYGENASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID; CARBON MONOXIDE; GLUCAGON; NITRIC OXIDE; NITRIC OXIDE DONOR; PROSTACYCLIN; SOMATOSTATIN DERIVATIVE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VASOPRESSIN DERIVATIVE;

HEMODYNAMICS; HYDRODYNAMICS; INFERIOR CAVA VEIN; LIVER CIRRHOSIS; MATHEMATICAL ANALYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA VOLUME; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; REVIEW; SPLANCHNIC BLOOD FLOW; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION;

EID: 3142777237     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13062895     Document Type: Review

References (135)

1. Shibayama Y, Nakata K. Localization of increased hepatic vascular resistance in liver cirrhosis. Hepatology 1985;5:643-7.
2. Fernández-Varo G, Ros J, Morales-Ruiz M, Cejudo-Martín P, Arroyo V, Sole M, et al. Nitric oxide synthase 3-dependent vascular remodeling and circulatory dysfunction in cirrhosis. Am J Pathol 2003;162:1985-93.
3. Bosch J, García-Pagán JC. Complications of cirrhosis. 1. Portal hypertension. J Hepatol 2000;32:141-56.
4. Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999;353:139-42.
5. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-501.
6. García-Pagán JC, Escorsell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Semin Liver Dis 1999;19:427-38.
7. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000;124:1599-607.
8. Sikuler E, Groszmann RJ. Interaction of flow and resistance in maintenance of portal hypertension in a rat model. Am J Physiol 1986;250:G205-G12.
9. th ed. Philadelphia: Lippincott Williams & Wilkins, 2003; p. 429-86.
10. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995;21:1238-47.
11. Bathal PS, Grossmann HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985;1:325-9.
12. Zhang JX, Pegoli Jr W, Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physiol Gastrointest Liver Physiol 1994;29:G264-G632.
13. Pinzani M, Gentilini P. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 1999;19:397-410.
14. Pinzani M, Failli P, Ruocco C, Casini A, Milani S, Baldi E, et al. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest 1992;90:642-6.
15. Bataller R, Ginés P, Nicolás JM, Gorbig MN, García-Ramallo E, Gasull X, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000;118:1149-56.
16. Bataller R, Nicolás JM, Ginés P, Esteve A, Nieves GM, García-Ramallo E, et al. Arginine vasopressin induces contraction and stimulates growth of cultured human hepatic stellate cells. Gastroenterology 1997;113:615-24.
17. Gorbig MN, Ginés P, Bataller R, Nicolás JM, García-Ramallo E, Tobias E, et al. Atrial natriuretic peptide antagonizes endothelin-induced calcium increase and cell contraction in cultured human hepatic stellate cells. Hepatology 1999;30:501-9.
18. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996;24:233-40.
19. Kawada N, Tran-Thi TA, Klein H, Decker K. The contraction of hepatic stellate (lto) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem 1993;213:815-23.
20. Shiomi M, Wakabayashi Y, Sano T, Shinoda Y, Nimura Y, Ishimura Y, et al. Nitric oxide suppression reversibly attenuates mitochondrial dysfunction and cholestasis in endotoxemic rat liver. Hepatology 1998;27:108-15.
21. Kaneda K, Sogawa M, Matsumara A, Cho A, Kawada N. Endothelin-1 induced vasoconstriction causes a significant increase in portal pressure of rat liver: localized constrictive effect on the the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology 1998;27:735-47.
22. Loureiro-Silva MR, Cadelina GW, Groszmann RJ. Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas. Am J Physiol Gastrointest Liver Physiol 2003;284:G567-G74.
23. Shah V, Haddad FG, García-Cardena G, Frangos JA, Mennone A, Groszmann RJ, et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest 1997;100:2923-30.
24. Greenway CV, Stark RD. Hepatic vascular bed. Physiol Rev 1971;51:23-65.
25. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998;28:926-31.
26. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998;114:344-51.
27. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999;117:1222-8.
28. Shah V, Cao S, Hendrickson H, Yao J, Katusic ZS. Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. Am J Physiol Gastrointest Liver Physiol 2001;280:G1209-G16.
29. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002;35:478-91.
30. Bellis L, Berzigotti A, Abraldes JG, Moitinho E, García- Pagán JC, Bosch J, et al. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology 2003;37:378-84.
31. Van de CM, Omasta A, Janssens S, Roskams T, Desmet V, Nevens F, et al. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut 2002;51:440-5.
32. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001;299:818-24.
33. Yokomori H, Oda M, Ogi M, Sakai K, Ishii H. Enhanced expression of endothelial nitric oxide synthase and caveolin-1 in human cirrhosis. Liver 2002;22:150-8.
34. Morales-Ruiz M, Cejudo-Martín P, Fernández-Varo G, Tugues S, Ros J, Angeli P, et al. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology 2003;125:522-31.
35. Dudenhoefer AA, Loureiro-Silva MR, Cadelina GW, Gupta T, Groszmann RJ. Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers. Hepatology 2002;36:381-5.
36. Van De CM, Van Pelt JF, Nevens F, Fevery J, Reichen J. Low NO bioavailability in CCl4 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: a comparison of two portal hypertensive rat models with healthy controls. Comp Hepatol 2003;2:2.
37. Fiorucci S, Antonelli E, Morelli O, Mencarelli A, Casini A, Mello T, et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci U S A 2001;98:8897-902.
38. Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000;105:741-8.
39. García-Pagán JC, Feu F, Navasa M, Bru C, Ruiz A, Bosch J, et al. Long-term haemodynamic effects of isosorbide 5-mono-nitrate in patients with cirrhosis and portal hypertension. J Hepatol 1990;11:189-95.
40. Salmerón JM, Ruiz A, Ginés A, García-Pagán JC, Ginés P, Feu F, et al. Renal effects of acute isosorbide-5- mononitrate administration in cirrhosis. Hepatology 1993;17:800-6.
41. García-Pagán JC, Villanueva C, Vila MC, Albillos A, Genesca J, Ruiz-del-Árbol L, et al. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. Gastroenterology 2001;121:908-14.
42. Loureiro-Silva MR, Cadelina G, Iwakiri Y, Groszmann RJ. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol 2003;39:940-6.
43. Zafra C, Abraldes JG, Cortez C, Berzigotti A, Tarantino I, García-Pagán JC. Simvastatin ammeliorates the increased hepatic vascular tone in patients with cirrhosis. J Hepatol 2003;38(Suppl 2):12A.
44. Suematsu M, Goda N, Sano T, Kashiwagi S, Egawa T, Shinoda Y, et al. Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest 1995;96:2431-7.
45. Wakabayashi Y, Takamiya R, Mizuki A, Kyokane T, Goda N, Yamaguchi T, et al. Carbon monoxide overproduced by heme oxygenase-1 causes a reduction of vascular resistance in perfused rat liver. Am J Physiol 1999;277:G1088-G96.
46. Makino N, Suematsu M, Sugiura Y, Morikawa H, Shiomi S, Goda N, et al. Altered expression of heme oxygenase-1 in the livers of patients with portal hypertensive diseases. Hepatology 2001;33:32-42.
47. Ballet F, Chretien Y, Rey C, Poupon R. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmaco Exp Ther 1988;244:233-5.
48. Graupera M, García-Pagán JC, Abraldes JG, Peralta C, Bragulat M, Corominola H, et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 2003;37:172-81.
49. Graupera M, García-Pagán JC, González-Abraldes J, Bosch J, Rodes J. Cirrhotic livers exhibit a hyperresponse to methoxamine. Role of nitric oxide and eicosanoids. J Hepatol 2001;34:66A.
50. Titos E, Claria J, Bataller R, Bosch-Marce M, Ginés P, Jiménez W, et al. Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology 2000;119:794-805.
51. Pinzani M, Milani S, De Franco R, Grappone C, Caligiuri A, Gentilini A, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996;110:534-48.
52. Moller S, Gulberg V, Henriksen JH, Gerbes AL. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol 1995;23:135-44.
53. Bosch J, Arroyo V, Betriu A, Mas A, Carrilho F, Rivera F, et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980;78:92-9.
54. Arroyo V, Planas R, Gaya J, Deulofeu R, Rimola A, Pérez-Ayuso RM, et al. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 1983;13:271-8.
55. Grossman HJ, Grossman VL, Bhathal PS. Enhanced vaso-constrictor response of the isolated perfused cirrhotic rat liver to humoral vasoconstrictor substances found in portal venous blood. J Gastroenterol Hepatol 1992;7:283-7.
56. Graupera M, García-Pagán JC, Titos E, Claria J, Massaguer A, Bosch J, et al. 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology 2002;122:387-93.
57. Graupera M, García-Pagán JC, Parés M, Abraldes JG, Rosello J, Bosch J, et al. Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol 2003;39:515-21.
58. Asbert M, Ginés A, Ginés P, Jiménez W, Claria J, Saló J, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993;104:1485-91.
59. Elliot AJ, Vo LT, Grossman VL, Bhathal PS, Grossman HJ. Endothelin-induced vasoconstriction in isolated perfused liver preparations from normal and cirrhotic rats. J Gastroenterol Hepatol 1997;12:314-8.
60. Clozel M, Gray GA, Breu V, Loffler BM, Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vaso-constriction in vivo. Biochem Biophys Res Commun 1992;186:867-73.
61. Reichen J, Gerbes AL, Steiner MJ, Sagesser H, Clozel M. The effect of endothelin and its antagonist bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol 1998;28:1020-30.
62. Sogni P, Moreau R, Gomola A, Gadano A, Cailmail S, Calmus Y, et al. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology 1998;28:655-9.
63. Poo JL, Jiménez W, María MR, Bosch-Marce M, Bordas N, Morales-Ruiz M, et al. Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects. Gastroenterology 1999;116:161-7.
64. Cho JJ, Hocher B, Herbst H, Jia JD, Ruehl M, Hahn EG, et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000;118:1169-78.
65. Kojima H, Sakurai S, Kuriyama S, Yoshiji H, Imazu H, Uemura M, et al. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo. J Hepatol 2001;34:805-11.
66. Segel N, Bayley TJ, Paton A, et al. The effects of synthetic vasopressin and angiotensin on the circulation in cirrhosis of the liver. Clin Sci 1963;25:43-55.
67. Bataller R, Sancho-Bru P, Ginés P, Lora JM, Al Garawi A, Solé M, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003;125:117-25.
68. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
69. González-Abraldes J, Albillos A, Banares R, Del Árbol LR, Moitinho E, Rodríguez C, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001;121:382-8.
70. Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001;121:389-95.
71. Titos E, Claria J, Planaguma A, López-Parra M, Villamor N, Parrizas M, et al. Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. FASEB J 2003;17:1745-7.
72. Albillos A, Lledó JL, Banares R, Rossi I, Iborra J, Calleja JL, et al. Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. Hepatology 1994;20:611-7.
73. Albillos A, Lledó JL, Rossi I, Pérez-Paramo M, Tabuenca MJ, Banares R, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995;109:1257-65.
74. Sumanovski LT, Battegay E, Stumm M, Van der KM, Sieber CC. Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Hepatology 1999;29:1044-9.
75. Sieber CC, Sumanovski LT, Stumm M, Van der KM, Battegay E. In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J Hepatol 2001;34:644-50.
76. Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using gamma-labeled microspheres. Am J Physiol 1981;240:G371-G5.
77. Mosca P, Lee FY, Kaumann AJ, Groszmann RJ. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. Am J Physiol 1992;263:G544-G50.
78. Chan CC, Lee FY, Wang SS, Chang FY, Lin HC, Chu CJ, et al. Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology 1999;30:630-5.
79. Chan CC, Wang SS, Lee FY, Chang FY, Lin HC, Chu CJ, et al. Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats. Hepatology 2001;33:816-20.
80. Huang HC, Lee FY, Chan CC, Chang FY, Wang SS, Lin HC, et al. Effects of somatostatin and octreotide on portal-systemic collaterals in portal hypertensive rats. J Hepatol 2002;36:163-8.
81. Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. Hepatology 1985;5:97-101.
82. Kowalski HJ, Abelman WH. The cardiac output at rest in Laennec cirrhosis. J Clin Invest 1953;32:1025-33.
83. Reuben A. The way to a man's heart is through his liver. Hepatology 2003;37:1500-2.
84. Lebrec D, Bataille C, Bercoff E, Valla D. Hemodynamic changes in patients with portal venous obstruction. Hepatology 1983;3:550-3.
85. Denie C, Vachiery F, Elman A, Soupison T, Gadano A, Moreau R, et al. Systemic and splanchnic hemodynamic changes in patients with hepatic schistosomiasis. Liver 1996;16:309-12.
86. Vorobioff J, Bredfeldt J, Groszmann RJ. Hyperdynamic circulation in a portal hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983;244:G52-G6.
87. Vorobioff J, Bredfeldt JE, Grossmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984;87:1120-3.
88. Grossmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences [editorial]. Hepatology 1994;20:1359-63.
89. Benoit JN, Barrowman JA, Harper SL, Kvietys PR, Granger DN. Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. Am J Physiol 1984;247:G486-G93.
90. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986;6:287-98.
91. Gomis R, Fernández-Álvarez J, Pizcueta P, Fernández M, Casamitjana R, Bosch J, et al. Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation. Hepatology 1994;19:1257-61.
92. Benoit JN, Zimmerman B, Premen AJ, Go VL, Granger DN. Role of glucagon in splanchnic hyperemia of chronic portal hypertension. Am J Physiol 1986;251:G674-G7.
93. Kravetz D, Bosch J, Arderiu MT, Pizcueta MP, Casamitjana R, Rivera F, et al. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 1988;254:G322-G8.
94. Pizcueta MP, García-Pagán JC, Fernández M, Casamitjana R, Bosch J, Rodés J. Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation. Gastroenterology 1991;101:1710-5.
95. Albillos A, Rossi I, Iborra J, Lledó JL, Calleja JL, Barrios C, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994;21:88-94.
96. Abraldes JG, Bosch J. Somatostatin and analogues in portal hypertension. Hepatology 2002;35:1305-12.
97. Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology 2001;120:975-83.
98. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991;337:776.
99. Guarner C, Soriano G, Tomás A, Bulbena O, Novella MT, Balanzo J, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993;18:1139-43.
100. Battista S, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G. Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 1997;26:75-80.
101. Hori N, Wiest R. Enhanced relaease of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hepatology 1998;28:1467-73.
102. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992;103:235-9.
103. Pizcueta P, Piqué JM, Fernández M, Bosch J, Rodés J, Whittle BJR, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992;103:1909-15.
104. Pizcueta MP, Piqué JM, Bosch J, Whittle BJR, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992;105:105-84.
105. Lee FY, Colombato LA, Albillos A, Groszmann RJ. Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993;105:1464-70.
106. García-Pagán JC, Fernández M, Bernadich C, Pizcueta P, Piqué JM, Bosch J, et al. Effects of continued nitric oxide inhibition on the development of the portal hypertensive syndrome following portal vein stenosis in the rat. Am J Physiol 1994;30:984-90.
107. Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 2002;283:G1074-G81.
108. Iwakiri Y, Tsai MH, McCabe TJ, Gratton JP, Fulton D, Groszmann RJ, et al. Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol 2002;282:H2084-H90.
109. Fernández M, García-Pagán JC, Casadevall M, Bernadich C, Piera C, Whittle BJ, et al. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. Gastroenterology 1995;108:1487-95.
110. Martin PY, Xu DL, Niederberger M, Weigert A, Tsai P, St. John J, et al. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol 1996;270:F494-F9.
111. Wiest R, Das S, Cadelina G, García-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999;104:1223-33.
112. Shah V, Wiest R, García-Cardena G, Cadelina G, Groszmann RJ, Sessa WC. Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol 1999;277:G463-G8.
113. Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999;276:G1043-G51.
114. Tsai MH, Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 2003;125:1452-61.
115. Albillos A, De la Hera A, González M, Moya JL, Calleja JL, Monserrat J, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003;37:208-17.
116. Bernadich C, Bandi JC, Piera C, Bosch J, Rodés J. Circulatory effects of graded diversion of portal blood flow to the systemic circulation in rats: role of nitric oxide. Hepatology 1997;26:262-7.
117. Bandi JC, Fernández M, Bernadich C, De Lacy AM, García-Pagán JC, Bosch J, et al. Hyperkinetic circulation and decreased sensitivity to vasoconstrictors following portacaval shunt in the rat. Effects of chronic nitric oxide inhibition. J Hepatol 1999;31:719-24.
118. La Villa G, Barletta G, Pantaleo P, Del Bene R, Vizzutti F, Vecchiarino S, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001;34:19-27.
119. Forrest EH, Jones AL, Dillon JF, Walker J, Hayes PC. The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis. J Hepatol 1995;23:254-8.
120. Sitzmann JV, Bulkley GB. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension. Ann Surg 1989;209:322-7.
121. Guarner C, Soriano G, Such J, Teixidó M, Ramis I, Bulbena O, et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination [véanse comentarios]. Gastroenterology 1992;102:303-9.
122. Potenza MA, Botrugno OA, De Salvia MA, Lerro G, Nacci C, Marasciulo FL, et al. Endothelial COX-1 and -2 differentially affect reactivity of MVB in portal hypertensive rats. Am J Physiol Gastrointest Liver Physiol 2002;283:G587-G94.
123. Fernández M, García-Pagán JC, Casadevall M, Mourelle M, Pique JM, Bosch J, et al. Acute and chronic cyclooxygenase blockade in portal hypertensive rats. Influence on nitric oxide biosynthesis. Gastroenterology 1996;110:1529-35.
124. Hou MC, Cahill PA, Zhang S, Wang YN, Hendrickson RJ, Redmond EM, et al. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology 1998;27:20-7.
125. Bruix J, Bosch J, Kravetz D, Mastai R, Rodés J. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985;88:430-5.
126. Fernández M, Bonkovsky HL. Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. Hepatology 1999;29:1672-9.
127. Fernández M, Lambrecht RW, Bonkovsky HL. Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: role in modulating mesenteric vascular reactivity. J Hepatol 2001;34:812-7.
128. Bàtkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001;7:827-32.
129. Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martón P, Fernández-Varo G, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002;122:85-93.
130. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998;12:1035-44.
131. Ginés P, Martín PY, Niederberger M. Prognostic significance of renal dysfunction in cirrhosis. Kidney Int Suppl 1997;61:S77-S82.
132. Genecin P, Polio J, Groszmann RJ. Na restriction blunts expansion of plasma volume and ameliorates hyperdynamic circulation in portal hypertension. Am J Physiol 1990;259:G498-G503.
133. García-Pagán JC, Salmerón JM, Feu F, Luca A, Ginés P, Pizcueta P, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994;19:1095-9.
134. Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and sodium retention in prehepatic portal hypertension [véanse comentarios]. Gastroenterology 1992;102:931-5.
135. Colombato LA, Albillos A, Groszmann RJ. The role of central blood volume in the development of sodium retention in portal hypertensive rats. Gastroenterology 1996;110:193-8.